Market capitalization | $307.52m |
Enterprise Value | $259.53m |
P/E (TTM) P/E ratio | 19.37 |
EV/FCF (TTM) EV/FCF | 23.92 |
EV/Sales (TTM) EV/Sales | 1.68 |
P/S ratio (TTM) P/S ratio | 1.99 |
P/B ratio (TTM) P/B ratio | 1.22 |
Revenue growth (TTM) Revenue growth | 6.01% |
Revenue (TTM) Revenue | $154.57m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a Kamada Ltd forecast:
2 Analysts have issued a Kamada Ltd forecast:
Jun '24 |
+/-
%
|
||
Revenue | 155 155 |
6%
6%
|
|
Gross Profit | 65 65 |
19%
19%
|
|
EBITDA | 30 30 |
27%
27%
|
EBIT (Operating Income) EBIT | 17 17 |
53%
53%
|
Net Profit | 15 15 |
339%
339%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
Head office | Israel |
CEO | Amir London |
Employees | 378 |
Founded | 1990 |
Website | www.kamada.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.